Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pick Your #1 Sort Of Espresso - 2Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- 3NASA's Voyager 1 set to achieve historic distance from Earth
- 4Reclassifying Achievement: Individual Accounts of Seeking after Interests
- 5Carry Nature Inside with These Staggering Plant Decisions
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- Winona Ryder didn't take the 'Stranger Things' plot lightly. How 'otherworldly' grief and a kidnapping in her hometown informed her character.
- 'Seditious behavior': Trump accuses Democrats who made video reminding the military not to follow illegal orders of a crime — but is it?
- Evaluated Smartwatches for Wellness Devotees
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- 'A completely new manufacturing frontier': Space Forge fires up 1st commercial semiconductor factory in space
- Sought-After Extravagance Ocean side Objections for a Lovely Escape
- We may have one thing in common with jellyfish, new research finds
- Famous Places to get-away for Americans
